AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

Boehringer Ingelheim, a leading research-driven biopharmaceutical company ... about CRM diseases and discussing the latest treatment advances, this event supports us in fulfilling our company’s ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

At the 2024 USPOULTRY Live Production, Welfare, and Biosecurity Seminar, experts highlighted key strategies for maintaining poultry health amidst challenges such as highly pathogenic avian influenza ...

Schaal discussed bacterial diseases in layers. According to Schaal, there are three elements impacting poultry immune health and performance — the bird, the environment and the pathogens — also known ...

The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

SAN FRANCISCO, October 16, 2024--GoodRx (NASDAQ: GDRX), the leading prescription savings platform in the U.S., today announced consumers will soon be able to use Affirm to pay over time for select ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

QUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery. Strategic partnership with the Research Institute of Molecular Patholog ...

Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...

An interim analysis from a long-term open-label extension study has underlined the clinical efficacy and safety of ...